Puma Biotechnology (PBYI) relies on one product. It has weak fundamentals and has struggled to grow sales. PBYI stock has surged 91% over the past year, driven by technical momentum and speculative trading spikes. Despite technical “Buy” signals, analyst sentiment is mixed, with most rating PBYI as “Hold” or “Sell.” With stagnant revenue, declining earnings, and only one product, PBYI lacks compelling long-term investment appeal. Today’s Featured Stock Valued at $303 million, Puma Biotechnology ...

Financial Performance - Puma Biotechnology reported first-quarter 2025 adjusted earnings of 10 cents per share, exceeding the Zacks Consensus Estimate of 2 cents, compared to a loss of 5 cents per share in the same quarter last year [1] - Total revenues for the quarter were $46.0 million, surpassing the Zacks Consensus Estimate of $44.0 million, with a year-over-year increase of 5% attributed to higher product revenues [1][2] - Product revenues from Nerlynx totaled $43.1 million, reflecting a 7% year-over-year increase and slightly above the guidance of $41-$43 million, although there was a sequential decline of 20.7% [5] - Royalty revenues amounted to $2.9 million, down from $3.5 million in the year-ago quarter but exceeding the model estimate of $1.7 million [6] Cost Management - Total operating costs for the quarter were $42.0 million, a decrease of 9% year over year [6] - Selling, general and administrative expenses declined by 19.2% year over year to $17.6 million, primarily due to lower legal fees [6] - Research and development expenses totaled $13.8 million, reflecting a 1.5% year-over-year increase [7] Future Guidance - Puma Biotechnology maintained its financial guidance for 2025, expecting Nerlynx's product sales to be in the range of $192-$198 million and royalty revenues between $20-$24 million [10] - For the second quarter of 2025, Nerlynx product sales are anticipated to be between $48-$50 million, with royalty revenues expected to be in the range of $2-$3 million [11] Pipeline Developments - The company is developing alisertib, an aurora kinase A inhibitor, for hormone receptor-positive breast cancer and small-cell lung cancer, having in-licensed the rights from Takeda in 2022 [12] - Puma Biotechnology is conducting a phase II study (ALISCA-Lung1) for alisertib as a monotherapy in extensive-stage small-cell lung cancer, with interim data expected in the second half of 2025 [13] - A phase II study (ALISCA-Breast1) is also underway for alisertib in combination with endocrine treatment for chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer, with initial data expected in the second half of 2025 [14] Stock Performance - Shares of Puma Biotechnology increased by 4.2% in after-hours trading on May 8 due to better-than-expected results [2] - The stock has risen 0.7% year to date, contrasting with an 8.4% decline in the industry [3]